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Capillary electrophoresis (CE) has emerged as a powerful technique for comprehensive physicochemical
characterization of monoclonal antibodies (mAbs) as well as other therapeutic modalities. The method
provides high resolution separation and high sensitivity characterization for analysis of therapeutic
biomolecules. CE based techniques such as sodium dodecyl sulphate capillary gel electrophoresis (SDS-
CGE, also referred to as CE SDS), capillary zone electrophoresis (CZE) and imaged capillary isoelectric
focusing (iCIEF) have been increasingly adopted to assess size heterogeneity, glycosylation heterogeneity
and charge heterogeneity in mAbs and related therapeutic modalities. This paper reviews the latest
application developments of CE based methods for routine release testing, stability testing and in-depth
characterization. In addition, advantages and disadvantages of each of these techniques are critically
discussed.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Monoclonal antibodies (mAbs) and related therapeutic modal-
ities, e.g. highly glycosylated Fc-Fusions, bi- and tri-specific mAbs,
mAb-ADCs, mAb fragments, PEGylated proteins and other varieties
have entered the market or clinic [1] and represent a rapidly
growing class of therapeutics treating numerous diseases such as
cancer, autoimmune disorders, and various infectious diseases
including the culprit of the recent pandemic. mAbs alone have a
revenue potential of USD 300 billion by 2025 [2]. Due to their pro-
teinaceous nature, heterogeneity accumulates throughout bio-
processing, with potentially deleterious variants acquired from
mutations during translation, uncontrolled modifications after
translation (post-translational modifications, or PTMs), and degra-
dation events occurring during the complex manufacturing process
such as fermentation, purification and storage. PTMs of a singlen.kaur@aurobindo.com (H. Kaur).
r B.V. This is an open access article uprotein sequence can lead to large molecular diversity given the
number of functional groups subject to various reactions including
glycosylation, glycation, phosphorylation, etc. [3]. Protein degrada-
tion events are often chemical in nature and can lead to, amongst
other things, a reduction in efficacy or increase in aggregation and
even immunogenicity, and these events occur at varying rates
depending on sequence, formulation, and storage conditions [4].
Thus, stringent analytical methods are necessary to comprehen-
sively identify, characterize andmonitor these quality attributes and
ultimately to ensure the release of purified and efficacious drug
products at the clinic and commercial stages. The latter requires
validated testing be performed in a quality control (QC) laboratory
with fit-for-purpose instrumentation and use of appropriate refer-
ence controls and system suitability tests. The results need to fit
within set acceptance limits, or specifications, on the reported level
of purity, amount(s) of known impurities, potency, etc., to controlnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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feedback at each stage of the process [6]. Similar requirements apply
to the commercialization of biosimilars with the added expectation
of establishing comparability to the original product [7].
Capillary electrophoresis (CE) has proven to be an essential
separation technique for these purposes because of its fast analysis
times with minimal sample consumption, high resolution, general
adaptation into the QC environment, and equally importantly,
complementarity to chromatographic approaches. The most pop-
ular modes in the industry include capillary SDS gel electrophoresis
(SDS-CGE), capillary zone electrophoresis (CZE) and capillary iso-
electric focusing (regular cIEF and imaging iCIEF modes) [8e13],
with some modes readily hyphenated to mass spectrometry (MS),
and are routinely utilized to assess size, charge and glycosylation
heterogeneity of protein biologics.
2. SDS-CGE and size heterogeneity
Size heterogeneity is a critical aspect of the physicochemical
characterization of a biological product [ICH Q6B]. Product related
aggregates (dimers, tetramers and even multimers), also known as
high molecular weight (HMW) species, and fragments of low mo-
lecular weight (LMW) relative to the parent molecule are often
considered critical quality attributes requiring close monitoring
during manufacturing, release, stability and storage and must meet
set acceptance criteria to minimize the risk of negative immune
responses and/or reduction in potency [14e16].
SDS-CGE is used for the purpose of evaluating size heterogeneity
under denaturing conditions with platform reagents and auto-
mated instrumentation available from several commercial manu-
facturers that can be utilized in the QC space. The performance and
usability of some of the more commonly used instruments in the
industry have been compared [17]. The method proceeds as fol-
lows. Briefly, upon application of an electric field, SDS-protein
complexes, ideally of uniform surface charge densities, migrate
towards a detector window to produce an electropherogram of
peaks representing increasing size over time. The most common
(and commercial) approach uses a capillary consisting of an inner
surface composed of bare-fused silica and filled with a sieving
matrix of dextran cross-linked with borate and other components
which serve to alter electroosmotic flow (EOF) [18,19].
Ideally, during electromigration, sample proteins are to be in a
uniformly denatured and unfolded state with SDS bound at an
optimized ratio with the protein [20]. This may be challenging for2
proteins that, for example, contain PTMs or highly negatively-
charged domains resistant to SDS binding and include proteins
with relatively high kinetic stability [21,22]. Method-induced HMW
formation can be a consequence of a non-ideal SDS-protein ratio
and can be detected by observing unexpectedly large variations in
relative % values upon testing across the anticipated concentration
range of the assay [12]. Correction may require optimization of the
SDS-protein ratio and/or a change of detergent to one that binds
protein with higher affinity (Fig. 1A) [13]. Alteration of the
monomer/cross-linker ratio has also proven to be useful to increase
the resolution of highly glycosylated species [19] as well as
increasing the capillary length and optimizing denaturation tem-
perature (Fig. 1B) [23]. In addition, sample preparation requires
careful consideration of pH, denaturation time, and concentration
of a free-thiol alkylating agent to prevent disulfide scrambling, or
disulfide reductant etc., with a primary goal being the prevention of
excess method-induced fragmentation [24]. Achieving this goal
would predictably improve method robustness and reproducibility
and ensures that the observed fragments represent real species
present in the sample prior to treatment.
Optimal separation conditions would ensure adequate peak
quantification of product and product-related variants of interest,
either known or anticipated. The optimization process may require
testing of aged samples, specimens from in-process purification
steps, and samples forcibly degraded, e.g., by subjecting it to partial
reduction, deglycosylation, UV light exposure, high pH, high tem-
perature, and/or peroxide treatment [25]. For example, partial
sample reduction assessments are necessary if the upstream
fermentation process produces enzymatically-reduced mAb prod-
uct impurities [26] and peptide N-glycosidase (PNGase) deglyco-
sylation experiments ensure that a protein yielding a broad peak
profile is simply a homogeneous protein bound to a highly complex
network of N-glycan structures. Representative in-process samples
can be useful in the case of antibody-drug conjugates (ADCs) by
helping to identify the mAb-drug stoichiometry via comparison of
electropherograms of pre- and post-conjugated samples [27,28], or
to ensure clearance of monoclonal parental mAb impurities from
the target bispecific mAb product [29].
For a typical mAb, SDS-CGE is considered an “LMWmethod” due
to its ability to resolve product-related species smaller than the
parent molecule and complements size exclusion chromatography
(SEC) when needed to assess the larger HMWspecies [30]. SDS-CGE
is run under denaturing conditions thus can reveal variants not
observed by native SEC, for example, a fragmented protein held
Fig. 1. Improving CGE separation efficiencies when evaluating challenging protein modalities. A) Use of higher affinity detergents, in this case SHS in place of SDS, to improve the
resolution of the main peak of an Fc-fusion from a product impurity (with permission from Ref. [13]). B) Optimizing denaturing temperature and increasing the effective capillary
length from 10 to 20 cm to resolve two light chains with similar MW of a bi-specific mAb. Inset: 10 cm effective capillary length (modified with permission from Ref. [23]).
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and reducing conditions can reveal fragmentation not observed
under non-reducing conditions alone, for example, when a CAP256
mAb clip was shown to only be held together by an intra-disulfide
bond [32]. If an important size variant cannot be resolved from its
intact parent molecule due to relatively small molecular weight
(MW) differences, dropping the MW via reduction and/or enzy-
matic cleavage may be sufficient to achieve full resolution. For
example, accurate and quantitative tracking of the non-
glycosylated (NG) IgG variant, a variant linked to reduced bioac-
tivity and effector function [33], can be achieved by mAb reduction
or IdeS cleavage to fully resolve NG-Heavy Chain or NG-Fc/2 from
their parent molecules respectively [10].
When sensitivity is a concern, signal can be enhanced through
use of CEwith laser-induced fluorescence (LIF) detection [34] either
using native fluorescence or after proper labeling. SDS-CGE
microchip instrumentation using LIF (mSDS-CGE) has been widely
implemented in process development laboratories due to its high
sensitivity and throughput capabilities, but has had limited success
as a QC release method due to reproducibility concerns [35].
Although release testing typically does not require high
throughput, bridging this technology into commercial QC labora-
tories would minimize comparability risks inherent to switching
platforms mid-development [36]. To this end, recent vendor-driven
mSDS-CGE method improvements, including the addition of an
automated standard mAb calibration step helping to optimize dye
content within the capillary, have produced reproducibility results
comparable to the more established, lower throughput SDS-CGE
options, with % area relative standard deviations (RSDs) of ~1%
(intra-assay precision) to 4% (inter-assay precision) [17].
With regard to CGE peak variant characterization, online
hyphenation of MS to SDS-CGE has not yet been achieved at the
commercial stage and requires more indirect means [37,38].
The main bottleneck is MS-incompatibility of sieving matrix
components, such as SDS and high concentration co-ions,
although great strides have been taken to improve the situa-
tion, for example, the use of cyclodextrins in interface solutions
to sequester detergents [39].
3. Charge heterogeneity
Many protein variants differ in overall charge relative to the
parent molecule and can yield a large range of effects, from
complete inactivation to higher relative potency [40], and often3
cannot be separated by SDS-CGE due to their comparable MWs.
The most common charge variant monitoring methods in the
biotechnology industry include ion exchange chromatography
(IEX), capillary-based isoelectric focusing without (cIEF) or with
(iCIEF) capillary-wide imaging capability, and CZE [41]. Several
commercial instruments performing CZE and (i)cIEF have been
adopted into the QC space [42,43]. IEX will not be discussed here,
except to say that it has a valuable place in the industry with well-
established MS compatibility [44]. Note, however, that IEX, unlike
CZE and cIEF/iCIEF, does not separate analytes based on overall
charge, but on the charge available for interaction with the solid
phase. Thus, a particular proteoform could be separated by CE but
not by IEX thereby yielding complementary information as
orthogonal techniques. This difference can be important when
monitoring the profile of ADCs [45] since the physical character-
istics of the conjugated drug could interfere with the IEX solid-
phase interaction of the parent mAb. As discussed below and
shown in Fig. 2, iCIEF, CZE and its offshoots, such as micellar
electrokinetic chromatography (MEKC), are also not expected to
yield comparable profiles and together are uniquely informative
depending on the specific variant(s) under scrutiny [46]. MEKC
and other promising CZE derivatives will not be discussed in detail
here in order to focus on the most common methods utilized in
the industry today.
CZE migration rates primarily depend on the ratio of the overall
charge-to-hydrodynamic radii of the analytes. Typically, the sample
is injected as a plug at one end of a capillary filled with a back-
ground electrolyte (BGE) buffered at a pH providing the desired
mobilities and capable of maintaining a constant field strength.
Unlike IEF, isoelectric point (pI) identification is not possible,
however, its advantages are sensitivity, MS compatibility and high
throughput; the latter particularly when judiciously implementing
EOF. These characteristics are ideal for routine quality monitoring
tasks such as ensuring batch lot-to-lot conformity. Although EOF
can be advantageous in this regard, reproducibility suffers due in
large part to the instability of the zeta potential at the capillary
inner surface [47]. As with SDS-CGE, these challenges have been
largely overcome through use of excipients that virtually eliminate
EOF and protein-surface adhesion while using a bare-fused silica
capillary. Comparable peak profiles and CPA% within a standard
deviation of ± 0.9 were shown across companies [43], at least
within the target predicted pI range of 7.4 and 9.5. For this reason,
CZE has grown in popularity and is being added to biologics release
testing panels [48].
Fig. 2. iCIEF, CZE (MEKC), and IEX (Cation exchange chromatography, CEX) profiles of the NIST mAb standard. These results underscore how methods utilizing the same basic
separation principle (“separation by charge”) can produce different profiles. The method chosen for monitoring would depend on the method that best resolves the variant(s) of
interest (Reprinted with permission from Ref. [46]).
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identifying an effective isoelectric point, or pI, of a protein of in-
terest and of each of its charged variants via migration across a pH
gradient to the point of neutrality. Resolving power depends on
field strength and the slope of the linear pH gradient established
across the medium, with resolution improving with shallower
gradients. Theoretically, pIs differing by 0.01 pH units or less can
be separated [49], although the requirement is a concentrated
mixture of amphoteric compounds, or “ampholytes”, collectively
covering the pH range of interest with closely-spaced pIs. Each
ampholyte must contain functional groups with pKas closely
flanking its pI to provide the conductance needed to generate a
uniform field strength. Importantly, each protein analyte may
require its own solubilizers/stabilizers [50], e.g., DMSO, urea,
formamide or one if its derivatives [51], to ensure robust and
reproducible performance.
Ampholytic mixtures yielding linear pH gradients of various
slopes and ranges are readily available on the vendor market, e.g.
Bio-Lyte from Bio-Rad, Pharmalyte from Cytiva, Servalyte from
Serva Electrophoresis, and Aeslytes fromAES Ltd., and can bemixed
and matched to achieve a sufficiently resolved profile. Although
Pharmalyte lot-to-lot reproducibility has been demonstrated [52],
method development should include lot evaluations to ensure
reproducibility for the specific protein of interest, and salts and
other additives can impact the linearity of the ampholyte pH
gradient [53].4
Relative to conventional cIEF, iCIEF has become popular as a
monitoring, release and stability test due to its ability to visualize
the final, focused variant profile in real time without requiring
mobilization of the focused peaks towards a detector window
either by chemical or hydrodynamic means. Mobilization may
modify the profile [54] or negatively impact resolution due to
laminar flow [55], respectively. Recently it has achieved acceptance
by the FDA as a characterization and QC method based on its
common inclusion in IND and BLA submissions [56] with laboratory
support provided by multi-company demonstrations of precision,
robustness, etc., all satisfying Q2(R1) ICH guidelines [52,57].
Quantification limits (QLs) of approximately 2e4% of the total
protein load were demonstrated when detecting by UV absorbance
at 280 nm. This QL lowers several-fold when utilizing the natural
fluorescence of tryptophan, allowing an evaluation at lower protein
load [58].
With regard to the use of iCIEF as a release and stability test, the
reported pI of a typical mAb is simply the peak of highest relative
proportion [57]. Product release specifications early in the pipeline
may report total relative % acidic and basic species compared to the
reported pI. These species may be considered impurities in lieu of
characterization evidence identifying particular variant(s) as either
confirmed impurities or not, at which point adjustments are made
to the specifications [59]. Thus, limits on relative quantities of
allowable acidic and/or basic variants are set late in development
once the needed characterization data is collected. Due to its
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tion, biotechnology companies have utilized iCIEF internally as an
identification method for release of clinical material in place of the
relatively complex ELISA or peptide mapping methods [57]. How-
ever, it has been observed that two mAb therapeutics within the
same product portfolio can have virtually identical profiles, even
after subjecting the product to reducing and/or subunit analysis.
This indicates that the risk may be too high to implement iCIEF as a
standalone commercial-stage identity method and this risk would
increase if testing involved a CRO [60]. Perhaps the entrance of new
and complex modalities into the biotherapeutics space, in partic-
ular Fc fusions with their accompanying complex charge variant
profiles, may lower this risk. However, the tradeoff would be an
increased reliance on characterization tools like CE-MS and de-
mand for more innovative cartridge coatings and additives to
reduce non-specific interactions and increase sample solubility,
stability, proteoform resolution, and method robustness.
4. Glycosylation heterogeneity
N- and O-linked carbohydrates are the most commonly occur-
ring forms of protein glycosylation [61], with some exceptions such
as reported in Ref. [62]. In this review we will focus on the analysis
of N-glycan since this represents the vast majority of oligosaccha-
rides bound to marketed protein therapeutics.
Glycosylation at the conserved CH2 Asn297 site of mAbs and Fc
fusion proteins can greatly impact the pharmacokinetic (PK) and
pharmacodynamic (PD) properties of a protein [63]. Because of the
large number of linkage and positional options, glycosylation is
highly heterogeneous, resulting in numerous glycosylation patterns
[64], and this complexity varies by the host cell and by the
manipulation of bioprocessing parameters, such as growth phase,
nutrition, oxygen level, pH, temperature, etc. [65]. Taken together,
complex glycosylation has the potential to impact patient safety
and product efficacy, thus, requires glycan content testing at drug
product release to ensure profile consistency [66] and in-depth
characterization as discussed below.
CE-based N-glycan analysis can occur at four levels [67e69];
Intact (Level 1), subunit, (Level 2), peptide (Level 3), and released
glycan (Level 4). At Level 1, CZE and iCIEF can differentiate glycan-
altering modifications such as sialylation, acetylation, sulfation or
phosphorylation, due to their impact on the overall charge density
of the protein. As discussed earlier, SDS-CGE can readily differen-
tiate between the glycosylated an non-glycosylated product forms
[19]. Hyphenation of CE with MS is another excellent way to
conduct Level 1 analysis due to the availability of low flow interface
operations (nanoliter- or low microliter per minute) in either
sheathless or sheathflow setups, which result in excellent separa-
tion efficiency and high signal strength due to efficient ionization/
low ion suppression at these flow rates [69].
Level 2 analysis, as outlined earlier, can be done using SDS-CGE
to evaluate reduced/denatured and/or partially clipped forms using
endopeptidases [70] with CZE- or cIEF-MS providing detailed gly-
coform information [71].
Level 3 requires proteolytic digestion (e.g., trypsin) followed
by low nL/min flow rate CE-MS or CE-MS/MS analysis of the
resulting glycopeptides [68]. Analysis of glycosylation together
with the corresponding glycopeptides provides site specificity
information. Furthermore, peptide analytical approaches such as
isotope, isobaric and fluorescent labeling for quantification,
metabolic incorporation, and mass defect analysis can be
simultaneously accomplished using low flow sheathless in-
terfaces with different sheath liquid additives [72]. CE-MS also
enables linkage-isomer separation through targeted modification
of the isomers resulting in distinguishable mass analytes, e.g.,5
ethyl esterification of sialic acid-containing isomers of the pros-
tate specific antigen [73].
Finally, at Level 4, the attached carbohydrates are either chem-
ically or enzymatically removed from the polypeptide backbone and
analyzed at the released glycan level. Liquid phase separation-based
carbohydrate analysis, however, requires derivatization of the free
glycan structures with a UV or fluorescently active agent, and for CE
this tag should also be charged to support proper electromigration
[74,75]. Level 4 N-linked carbohydrate analysis starts with specific
enzymatic removal of the glycan moiety, in most instances using
PNGase F. This endoglycosidase releases most asparagine-linked
oligosaccharides except e.g., the alpha 1e3 core fucosylated ver-
sions, to mention the most important one. For efficient release, in
most instances the polypeptide chains should be unfolded to ensure
full access of the glycosidase, typically using mixtures of denaturing
and reducing agents such as SDS, dithiothreitol (DTT), iodoacetic
acid (IAA), etc. This is especially important for newmodalities, such
as fusion proteins and multi-specific antibodies, in which cases a
denaturing temperature gradient is suggested [76]. For labeling, the
most commonly used CE fluorescent agent is the triple negatively
charged 8-aminopyrene-1,3,6-trisulfonic acid (APTS), which binds
covalently via a classical Schiff-base formation reaction followed by
reduction to obtain a stable conjugate. The use of positively charged
tags is also possible, but not recommended for sialylated structures
as the net charge of the carbohydrate e dye complex can become
zero (equal number of negatively charged sialic acids and positive
charges on the tag) resulting in no differential electromigration.
Other labeling dyes have also emerged utilizing NHS ester-based
chemistries rather than the commonly used reductive amination
technique [74]. The applied labeling agents have to be added in large
excess to the derivatization reaction mixture in order to ensure
acceptable reaction speed, and associated parameters such as
temperature, derivatization time and catalyst concentration all have
to be optimized to improve reaction yields. Due to the large excess
of tagging agent, the labeled sample must be purified prior to
electrophoresis using either HILIC type micro-columns or magnetic
micro-particles [77]. In both instances, the cleanup process is based
on binding of the labeled glycans to the applied stationary phase
under high organic solvent conditionse typically acetonitrilee and
eluted by water. The entire workflow can be fully automated to
provide the required robustness of the approach for downstream
validation [78].
Detailed structural elucidation of the sugar structures including
positional and linkage information is either based on calculated
glucose unit (GU) values and an associated database search (www.
GlycoStore.com) [79] or by MS identification [80]. For GU calcula-
tion, either an oligosaccharide ladder is run prior to or after the
sample separation step or a bracketing standard set is co-injected.
Alternatively, the ladder can be co-injected with the sample using
tags with different excitation/emission wavelengths. In both in-
stances the GU based database search usually provides adequate
structural elucidation of the separated glycans [81].
When neither the GU value search nor MS analysis gives un-
ambiguous results, exoglycosidase digestion-based glycan
sequencing is necessary to properly identify the sequence of the
sugar components along with their positional and linkage infor-
mation [82]. This can include a type of sequencing workflow uti-
lizing multiple enzymes either consecutively or in an array format
to specifically release the carbohydrate building sugar monomers
one by one, starting from the non-reducing end of the oligosac-
charide structure, as shown in Fig. 3. For most biotherapeutics,
sialic acids are the usual capping residues at the non-reducing end,
which are readily released by appropriate neuraminidase enzymes
with alpha 2e3,4,6 or 8 specificities. Considering the most
frequently occurring glycan structures shown in Fig. 3,
Fig. 3. Fully automated capillary electrophoresis based carbohydrate sequencing of etanercept. Panel A: workflow of the consecutive exoglycosidase digestion steps, Ⓢ sample
injection, Ⓘ incubation, Ⓔ exoglycosidase enzyme addition. The dotted line depicts the temperature profile during the exoglycosidase digestion steps. Panel B: the resulting CE
separation traces after the addition of the exoglycosidases. With permission from Ref. [82].
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This particular treatment is of high importance since it can identify
any highly immunogenic alpha 1e3 Gal epitopes [83]. Next, the
GlcNAc residues are released, both antennary and bisecting types,
using appropriate hexosaminidase enzymes. Finally, the core fucose
is removed by fucosidase. Note that in rare cases arm fucosylation is
possible, at which case, the fucosidase should be used first because
its non-reducing capping position would inhibit further digestion
steps. The same thing is applicable for the alpha 1e3 Gal as that is
usually at the same non-reducing end position [83]. If necessary for
antennary positioning identification, the mannose residues can be
released by applying the corresponding 1e3 or 1e6 mannosidases
of the partially digested core [83]. The mannosidase enzyme be-
comes especially important in analyzing hybrid structures and
samples containing high mannose glycans. After each digestion
step, the target sample is re-analyzed by CE, and from themigration
time shifts and peak area changes the type and the number of the
removed residues can be readily calculated. Please note that
sequencing should start from the non-reductive end usually with
the removal of the sialic acids, followed by the galactoses and
GlcNAc residues in order to ensure that consecutively used en-
zymes are not inhibited by non-removed sugars.
5. CE-MS
The various complexmAb-relatedmodalities can yield relatively
highly complex charged-isoform profiles relative to a typical mAb.
Companies are combining one or more proteins in so-called com-
bination therapies, which further complicate the isoform profile
[84]. Consequently, such complexity underscores the importance of
MS characterization.
As mentioned earlier, MS-based methodologies are widely
used to support characterization and development testing of
biopharmaceuticals at various levels of analysis, from intact to6
peptide map to glycan release, and are becoming increasingly
popular even with the potential of GMP implementation [85].
Although LC-MS and LC-MS/MS are the predominant MS-based
hyphenated techniques, the role of CE-MS in the biopharmaceu-
tical field has increased and examples have been successfully
applied to the analysis of complex glycoproteins, ADCs, bispecifics,
and protein mixtures [86e89]. CE-MS can serve as an orthogonal
and complementary approach to LC-MS as discussed below and
shown in Fig. 4 [90] and its lack of stationary phase poses less risk
of nonspecific interaction and injection-to-injection carryover.
Electrospray ionization (ESI) is the most common MS ion
source for large molecule analysis including protein charge vari-
ants. Its integration with CE requires an interface, the purpose of
which is to maintain stable electric contact at the CE outlet elec-
trode and assist in steady spray formation by ESI [72]. Significant
amounts of effort have been devoted to CE-ESI interface design
and several comprehensive reviews have highlighted the tech-
nical innovations in terms of instrumentation and methodology,
e.g. Ref. [72]. The application of CE-MS is facilitated by these
dedicated designs and their commercialization, for example the
sheathless porous tip interface (commercialized as CESI 8000,
SCIEX, USA), coaxial sheath-flow interface (G1607B, Agilent
Technologies, USA) and nanoflow sheath liquid interface (EMASS-
II, CMP Scientific, USA).
The sheathless interface enables the BGE to be electrosprayed
directly from the CE capillary without additional dilution, giving
rise to enhanced sensitivity and has been used in characterization
of complex intact proteins, elucidation of their glycosylated struc-
tures and conformational heterogeneities, as well as identification
of low-abundance PTMs [86,91]. The method detection range of
protein biomarkers could be as low as ng/mL when combined with
a pre-concentration process [92]. Although compromised sensi-
tivitymay occur in sheath liquid interfaces due to dilution effects by
the liquid flow employed to maintain electrical contact,
Fig. 4. CEX-MS and CZE-MS comparative characterization of the monoclonal antibody cetuximab. pH gradient-based separation by CEX-MS and CZE-MS were both capable of
efficient separation of cetuximab charge variants with eight major peaks baseline resolved, although with different separation selectivity (Reprinted with permission from Ref. [90].
Copyright (2020) American Chemical Society).
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Sufficient robustness and accuracy assessments of sheath liquid has
been shown by studies characterizing degradation variants of mAbs
and their fragments via screening and monitoring of specific
modifications [93,94]. By coupling with immunoaffinity capture
techniques, sheath liquid CE-MS has also been used to evaluate
in vivo stability of fusion proteins through monitoring of protein
catabolites in serum samples [95].
iCIEF-MS analysis can be achieved by offline fractionation where
fractions are first collected, processed with MS-compatible com-
ponents if needed, and subsequently introduced into MS for char-
acterization. Although more time consuming and labor intensive,
offline fractionation is not limited to separation of analytes
requiring only MS-compatible components [93] and may be
necessary to fully characterize some highly complex proteins at the
intact level, for example highly glycosylated Fc-fusions [96]. More-
over, the labor intensive efforts can be alleviated by the availability
of preparative systems and high throughput methods [97].
Microchip CE-MS is a trending technology thanks to its fast
analysis time, high throughput, high sensitivity and low sample
consumption. The narrowing of hydraulic channels enables
implementation of higher field strengths which accelerates sample
movement and consequently reduces analysis time [72]. Innovative
capillary coatings have been applied to improve performance by
reducing EOF and protein adsorption [71,98]. Examples of micro-
chip iCIEF-MS and CZE-MS are now commercially available and
show great potential for applications such as early development
screening and monitoring of specific protein quality attributes
[71,99]. The integration of microchip capillary electrophoresis
based imaged isoelectric focusing with MS is a promising new
combination, allowing in-line peak identification of the separated
species [71]. Application of transillumination supporting wafer
materials enables direct monitoring of the separation and immo-
bilization steps prior to entrance of the focused molecules to the
mass spectrometer for structural elucidation. Recently, the utility of
microchip CZE-MS was demonstrated through its generation of a
native charge variant profile yielding several low abundant variants7
not observed by IEX-MS, achieving complementary results to
traditional LC-MS with relatively high sensitivity in minutes per
sample [90]. Note that the platform format of this technology and
its pre-mixed buffer kits can reduce method development and
optimization timelines [90]. That said, vendors, when possible,
should “open” platforms to accommodate molecules not fitting
within the typical paradigm by adjusting BGE compositions and/or
modifying locked method parameters.
6. Conclusion and future perspectives
The molecular complexity of mAbs and other therapeutic mo-
dalities requires a large variety of analytical methods to identify
and monitor deleterious modifications and degradation products.
CE has emerged as an important component of the overall testing
strategy as an orthogonal and complementary technique to LC in
the assessment of size, charge, and glycan heterogeneity. CE-MS
characterization has gained importance in the field due to its
high sensitivity and inherent structural elucidation potential.
Robust and reproducible non-hyphenated CGE, CZE, and cIEF/iCIEF
methods can be developed for testing at all stages of the
manufacturing process, from monitoring of upstream and in-
process samples to the release and stability testing of patient-
ready products. In particular, the versatility of the above dis-
cussed CE-based workflow for rapid analysis of complex glycan
structures at different levels, including linkage and positional
identification of isomers, is a promising addition to the in-process
control toolbox. As the biopharmaceutical industry continues to
diversify with increasingly complex modalities (relative to mAbs),
in particular bi-and tri-specific mAbs, conjugated proteins with
improved activity and/or PK (e.g. PEGylated, fatty acid conjugated,
and ADCs), highly N- and O-glycosylated Fc-fusions with high
melting temperatures, proteins utilizing specific glycans to
manipulate the immune response (e.g., fucosylated versus afuco-
sylated), etc., it will become increasingly important to properly
extract the complementary information only these CE methods can
provide.
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